查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857629

抗菌药物敏感性测试市场（按产品类型、测试方法、方法论、应用和最终用户划分）—全球预测，2025-2032年

Antimicrobial Susceptibility Testing Market by Product Type, Test Type, Method, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗菌药物敏感性测试市场规模将达到 64.3 亿美元，复合年增长率为 6.02%。

关键市场统计数据
基准年 2024 40.2亿美元
预计年份：2025年 42.5亿美元
预测年份 2032 64.3亿美元
复合年增长率 (%) 6.02%

一份简洁的策略性介绍，概述了抗菌药物敏感性检测的趋势、业务需求和诊断创新，旨在指导临床和研发决策。

抗菌药物敏感性试验是临床微生物学和治疗管理的基础，对全球的治疗决策、监测活动和药物开发平臺都产生深远的影响。本执行摘要总结了当前该领域的主要趋势、技术曲折点、监管压力和商业需求。本书旨在为实验室、医疗保健系统、药物研发和公共卫生领域的领导者提供简洁扼要、基于实证的简报，帮助他们更好地应对不断变化的临床和商业性需求。

自动化、分子诊断、劳动力限制和整合服务如何重塑实验室工作流程和诊断供应商关係

近年来，诊断技术、实验室操作以及支持抗菌药物管理的整个生态系统都发生了变革性变化。自动化程度正从独立的分析仪发展到完全整合的平台，这些平台整合了自动化系统、盘式分析仪和资料处理流程。这项变更不仅缩短了周转时间，还提高了可重复性和资料完整性，使大型中心能够在保证品质的前提下扩大侦测能力。同时，基因型鉴定方法和分子检测技术的进步提供了与传统表型检测互补的信息，加速了抗药性决定因素的识别，并为精准医疗提供了资讯。

在不断变化的关税环境下，评估贸易政策对诊断采购、试剂持续供应和资本采购选择的累积影响

政策变化，例如关税和跨境贸易成本的调整，会对诊断供应链和筹资策略产生连锁反应，进而影响设备采购、试剂供应和价格动态。当进口诊断组件或成品设备的关税提高时，实验室和製造商将面临更高的到岸成本，这往往迫使他们重新评估供应商合约和库存策略。有些机构会加速在地采购，寻找合适的供应商；而有些机构则会协商长期供应协议，以避免贸易波动带来的风险。此外，关税上涨还可能影响资本投资决策的时机，促使买家延长设备使用寿命或优先考虑模组化升级而非整体更换。

細項分析整合了产品、测试、方法、应用和最终用户观点，以确定创新和商业化的优先目标。

了解产品、测试、方法、应用和最终用户等细分领域之间的交集，对于协调研发重点、筹资策略和商业化计划至关重要。产品类型涵盖仪器、试剂盒和服务。仪器包括自动化系统和手动系统，可进一步细分为自动化分析仪和自动盘式分析仪。试剂盒分为抗生素敏感性测试试剂盒和微生物鑑定试剂盒，而服务则涵盖分析测试服务和客製化测试解决方案。这种产品层面的细分凸显了自动化投资与试剂组合或外包服务投资的不同之处，前者对耗材消耗、供应商锁定和工作流程重组的影响也截然不同。

诊断简介及美洲、欧洲、中东和非洲以及亚太地区的供应链策略

区域动态正在塑造需求模式和供应链策略，因此，对全球规划而言，细緻的跨区域视角至关重要。在美洲，大型医院网路、先进的临床实验室以及对抗菌药物管理的重视，加上支付方和监管机构的期望，共同推动了自动化和互联诊断平台的普及应用。确保试剂和耗材的稳定供应需要本地化的库存策略和长期的供应商关係。在欧洲、中东和非洲，监管环境的差异和资源的多样性导致了不同的应用路径。一些欧洲市场的领先实验室优先发展先进的分子诊断和自动化表型分析工作流程，而该地区的其他一些市场则更注重成本效益高、稳健可靠且基础设施有限的大规模部署方法。

仪器供应商、试剂专家和服务供应商之间的竞争动态和合作策略正在塑造平台整合和经常性收入模式。

竞争格局由成熟的诊断设备製造商、专业试剂製造商以及提供分析测试和客製化解决方案的服务供应商组成。现有设备供应商持续投资于平台整合、软体驱动的决策支援和互通性，以保持其在临床实验室的竞争力。同时，规模较小、更灵活的公司正在推进基因型检测和针对特定抗药性机制的专用试剂组，从而为寻求扩展检测专案的大型公司创造合作机会。服务供应商透过提供端到端的验证支援、远端设备监控以及旨在满足监管申报要求的客製化检测方案来脱颖而出。

为高阶主管提供可操作的建议，以增强韧性、加快自动化采用，并建立满足用户需求的差异化产品和服务。

领导者必须采取审慎行动，抓住机会，规避风险。首先，应优先投资自动化和互通软体，以减少人工操作，提高可重复性，并实现临床和研究环境中的可扩展测试。其次，应实现供应链多元化，对关键试剂和耗材的替代供应商进行资格认证，并建立合约机制，以便在供应中断时能够灵活承诺数量并优先履行义务。此外，还应加强诊断开发人员和最终用户之间的合​​作，共同设计检验测试和服务模式，以应对实际实验室的限制和监管要求。

结合一手访谈、技术检验和二手证据的稳健混合调查方法，确保了研究的实用性和方法论的严谨性。

调查方法，结合了初步访谈、严谨的二次验证与技术检验。初步数据透过实验室主任、采购主管、诊断试剂研发人员和服务供应商的结构化访谈收集，以了解他们的业务重点、采购驱动因素和创新蓝图。二次研究整合了同行评审文献、监管指南和技术白皮书，以检验定性检测方法和定量检测方法之间的差异，并了解自动化分析仪、自动盘式分析仪和分子检测方法的性能标准演变。

总结观点，应协调技术、营运和商业性策略，以实现先进药敏试验的临床和公共卫生效益。

抗菌药物敏感性检测正处于曲折点，技术创新、营运压力和政策动态正在交汇融合，重塑诊断实践。持续推进自动化、互补基因分型方法和数据驱动的管理工具，可望加速诊断并改善临床决策，同时也对验证、互通性和从业人员能力提出了新的要求。供应链的韧性和灵活的商业模式将影响实验室和研究机构采用新平台和检测方法的速度。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 采用快速微流体抗生素敏感性试验系统，实现同班次抗生素优化
  • 将人工智慧主导的影像分析整合到AST平台中，以提高结果准确性
  • 扩展基于次世代定序的药敏试验，以实现全面的抗药性分析
  • 自动扩散试验阅片器的出现降低了人工判读结果的差异性。
  • 针对多重抗药性病原体检测的多重药敏试验板的需求日益增长
  • 加速核准基于微孔盘的药敏试验试剂盒，以满足迫切的临床需求
  • 诊断公司与人工智慧新兴企业建立策略伙伴关係，共同开发AST分析技术
  • 实施云端基础的AST数据管理系统，用于即时监测报告

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的抗菌药物敏感性测试市场

  • 装置
    • 自动化系统
      • 自动分析仪
      • 自动盘式分析仪
    • 手动装置
  • 试剂和试剂盒
    • 抗生素敏感性检测试剂盒
    • 微生物鑑定试剂盒
  • 服务
    • 分析测试服务
    • 客製化检验解决方案

9. 依检测方法分類的抗菌药物敏感性检测市场

  • 抗菌药物敏感性试验
  • 抗真菌药物敏感性试验
  • 抗寄生虫药物敏感性试验
  • 抗病毒药物敏感性试验

第十章 依方法论分類的抗菌药物敏感性测试市场

  • 定性方法
    • 琼脂稀释法
    • 自动化药物敏感性检测方法
    • 纸锭扩散法
    • 基因分型方法
  • 定量方法
    • 肉汤大稀释法
    • Etest 方法

第十一章 按应用分類的抗菌药物敏感性测试市场

  • 临床诊断
  • 药物研发
  • 流行病学

第十二章：按最终用户分類的抗菌药物敏感性测试市场

  • 学术和政府研究机构
  • 医院和诊断中心
  • 製药和生物技术公司

13. 按地区分類的抗菌药物敏感性检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 抗菌药物敏感性测试市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国抗菌药物敏感性检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Accelerate Diagnostics, Inc.
    • Alifax Srl
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
    • Biological Safety Solutions Ltd/Oy
    • BioMerieux SA
    • Bruker Corporation
    • Creative Diagnostics
    • Danaher Corporation
    • Erba Lachema sro
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche AG
    • Himedia Laboratories Private Limited
    • INTEGRA Biosciences AG
    • Laboratorios Conda, SA
    • Launch Diagnostics Limited
    • Leading Biology, Inc.
    • Liofilchem Srl
    • Mast Group Ltd.
    • MP Biomedicals, LLC
    • Pfizer Inc.
    • Qiagen NV
    • QuantaMatrix Inc.
    • Resistell AG
    • Synoptics Group
    • Thermo Fisher Scientific Inc.
    • Zhuhai DL Biotech Co., Ltd.
Product Code: MRR-464C422F4BD3

The Antimicrobial Susceptibility Testing Market is projected to grow by USD 6.43 billion at a CAGR of 6.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.02 billion
Estimated Year [2025] USD 4.25 billion
Forecast Year [2032] USD 6.43 billion
CAGR (%) 6.02%

A concise strategic introduction framing antimicrobial susceptibility testing trends, operational imperatives, and diagnostic innovation that guide clinical and R&D decision-making

Antimicrobial susceptibility testing is a cornerstone of clinical microbiology and therapeutic stewardship, influencing treatment decisions, surveillance activities, and drug development pipelines worldwide. This executive summary synthesizes cross-cutting trends, technological inflection points, regulatory pressures, and operational imperatives shaping the field today. It aims to provide a concise, evidence-based briefing for leaders in laboratories, health systems, pharmaceutical development, and public health who must align capabilities with evolving clinical and commercial demands.

The landscape is defined by the convergence of automation, molecular diagnostics, and data-driven decision support. Faster time-to-result and improved reproducibility are driving investment in automated instruments and integrated workflows, while genotypic approaches complement phenotypic assays to give clinicians a richer understanding of resistance mechanisms. At the same time, regulatory scrutiny of diagnostic performance, reimbursement dynamics, and supply chain resiliency continue to affect implementation timelines and capital allocation. This introduction frames the topics addressed in the following sections and sets expectations for actionable insights that follow, positioning readers to evaluate strategic options in procurement, laboratory modernization, and collaborative research.

How automation, molecular diagnostics, workforce constraints, and integrated services are reshaping laboratory workflows and supplier relationships in diagnostics

Recent years have ushered in transformative shifts across diagnostic technology, laboratory operations, and the broader ecosystem that supports antimicrobial stewardship. Automation has moved beyond stand-alone analyzers toward fully integrated platforms that combine automated systems, plate readers, and connected data pipelines. This change not only reduces hands-on time but also elevates reproducibility and data integrity, enabling larger institutions to scale testing capacity while maintaining quality. Simultaneously, advances in genotypic methods and molecular panels are providing complementary insights to traditional phenotypic assays, accelerating identification of resistance determinants and informing precision therapy.

Workforce dynamics and laboratory consolidation are forcing organizations to rethink workflows; shortages of skilled technicians increase the value of automation and remote monitoring capabilities. Reagents and kits are evolving too, with manufacturers optimizing formulations for stability and compatibility with automated analyzers and automated plate readers to reduce variability and logistical burden. Services are expanding beyond routine analytical testing to offer custom testing solutions and advisory support for assay validation and regulatory submissions. Taken together, these forces are reshaping procurement priorities, vendor relationships, and the structure of diagnostic service offerings, prompting stakeholders to prioritize agile, interoperable solutions that support both clinical diagnostics and drug development pathways.

Evaluating cumulative trade policy impacts on diagnostic sourcing, reagent continuity, and capital procurement choices amid changing tariff environments

Policy shifts that alter duties and cross-border trade costs can ripple through diagnostic supply chains and procurement strategies, influencing instrument sourcing, reagent availability, and pricing dynamics. When tariffs increase on imported diagnostic components or finished instruments, laboratories and manufacturers face higher landed costs that often require re-evaluation of supplier contracts and inventory strategies. Some organizations respond by accelerating local sourcing where capable suppliers exist, while others negotiate long-term supply agreements to hedge exposure to trade volatility. In addition, higher tariffs can affect the cadence of capital investment decisions, prompting buyers to extend equipment lifecycles or prioritize modular upgrades over full platform replacements.

Beyond direct cost effects, tariff changes can create secondary impacts on innovation diffusion and service delivery. Manufacturers with geographically diversified production footprints may reallocate manufacturing to regions with preferential trade terms, which can alter lead times and qualification requirements for regulatory filings. Service providers that perform analytical testing and custom testing solutions may need to adjust pricing or revise cross-border service agreements to maintain margins. For clinical entities and research organizations, the pragmatic response often combines inventory buffering, supplier diversification, and closer collaboration with vendors to secure continuity of reagents and critical consumables. Ultimately, the cumulative effects of tariff shifts emphasize the importance of resilient sourcing strategies, contractual flexibility, and scenario planning to manage supply chain risk while sustaining diagnostic quality and operational continuity.

Integrated segmentation analysis that aligns product, test, method, application, and end-user perspectives to reveal priority targets for innovation and commercialization

Understanding how product, test, method, application, and end-user segments intersect is essential to aligning R&D priorities, procurement strategies, and commercialization plans. Based on product type, the landscape spans instruments, reagents and kits, and services; instruments include automated systems and manual instruments, with automated systems further differentiated into automated analyzers and automated plate readers; reagents and kits divide into antibiotic susceptibility kits and microbial identification kits; and services encompass analytical testing services and custom testing solutions. This product-level distinction underscores that investments in automation will carry different implications for consumable consumption, vendor lock-in, and workflow redesign than investments in reagent portfolios or outsourced services.

Test type segmentation reflects clinical and research needs across antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing, and antiviral susceptibility testing, each with distinct methodological requirements and clinical urgency. Method segmentation separates qualitative and quantitative approaches; qualitative methods include agar dilution, automated AST, disk diffusion, and genotypic methods, while quantitative methods comprise broth macrodilution and the Etest method. These methodological differences influence laboratory throughput, interpretive complexity, and regulatory validation pathways. Application segmentation shows demand centers in clinical diagnostics, drug discovery and development, and epidemiology, which in turn shape acceptance criteria and data deliverables. Finally, end-user segmentation identifies academic and government research institutes, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies as primary consumers, each with unique procurement cycles, performance expectations, and budgetary constraints. Combining these lenses reveals where innovation will be most valuable, which channels require targeted commercial strategies, and how validation and service models should be configured to meet user needs.

Regional diagnostic adoption and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform tailored commercial approaches

Regional dynamics shape both demand patterns and supply chain strategies, and a nuanced view across geographies is critical for global planning. In the Americas, demand is driven by large hospital networks, advanced clinical laboratories, and a strong emphasis on antimicrobial stewardship tied to payer and regulatory expectations, which favors adoption of automation and connected diagnostic platforms. Supply chain resilience is a recurring concern, motivating local inventory strategies and longer-term supplier relationships to ensure steady access to reagents and consumables. Across Europe, Middle East & Africa, regulatory heterogeneity and resource variability create differentiated adoption trajectories; leading laboratories in some European markets prioritize advanced molecular and automated phenotypic workflows, while parts of the broader region focus on cost-effective, robust methods that can be deployed at scale with constrained infrastructure.

Asia-Pacific presents a mixed picture of rapid capacity expansion, significant public health-driven surveillance programs, and growing domestic manufacturing capabilities for reagents and instruments. Investment in laboratory infrastructure and public health surveillance is increasing in many markets, bolstering demand for both automated systems and analytical testing services. These regional contrasts mean that product design, commercial models, and partnership strategies must be tailored; solutions that succeed in one geography may need adaptation in pricing, service delivery, and regulatory support to achieve traction elsewhere. Cross-border collaboration and strategic regional partnerships can help bridge capability gaps, accelerate technology transfer, and align supply networks with regional priorities.

Competitive dynamics and partnership strategies among instrument vendors, reagent specialists, and service providers shaping platform integration and recurring revenue models

The competitive landscape is being shaped by a mix of established diagnostic manufacturers, specialized reagent suppliers, and service providers offering analytical testing and custom solutions. Incumbent instrument vendors continue to invest in platform integration, software-enabled decision support, and interoperability to maintain clinical laboratory relevance. At the same time, smaller and more agile firms are advancing genotypic assays and niche reagent kits that address specific resistance mechanisms, enabling partnership opportunities with larger firms seeking to broaden their test menus. Service providers are differentiating by offering end-to-end validation support, remote instrument monitoring, and customized testing panels designed to meet regulatory submission needs.

Strategic behavior includes forming alliances to accelerate market entry, pursuing acquisitions to fill portfolio gaps, and expanding service capabilities to capture recurring revenue from consumables and testing contracts. Manufacturers are also investing in digital tools that aggregate susceptibility data for local surveillance and stewardship programs, creating stickiness and value beyond the instrument sale. For pharmaceutical and biotechnology companies, collaborations with diagnostic developers and contract service providers are increasingly important to de-risk antimicrobial drug development through integrated testing strategies. Overall, competitive advantage accrues to organizations that combine technical excellence with adaptable commercial models, robust supply chains, and strong customer support frameworks.

Actionable recommendations for executives to strengthen resilience, accelerate automation adoption, and build differentiated product and service offerings aligned with user needs

Leaders must act deliberately to capture opportunities and mitigate risk. First, prioritize investments in automation and interoperable software that reduce manual workload, improve reproducibility, and enable scalable testing across clinical and research settings. Next, diversify supply chains and qualify alternate suppliers for key reagents and consumables, and establish contractual mechanisms that allow flexible volume commitments and priority fulfillment during supply disruptions. Strengthen collaboration between diagnostic developers and end users by co-designing validation studies and service models that address real-world laboratory constraints and regulatory expectations.

Additionally, invest in workforce development to close skill gaps through targeted training programs, remote monitoring tools, and workflow redesign that optimize the use of scarce specialist talent. For companies commercializing tests or instruments, adopt flexible pricing and service bundles that reflect the needs of distinct end users such as academic research centers, hospital systems, and pharmaceutical development teams. Finally, integrate surveillance data products and stewardship support into offerings to create differentiated value, foster long-term customer relationships, and demonstrate public health impact. These steps create a pragmatic roadmap to balance short-term resilience with long-term growth and innovation.

Robust mixed-methods research approach combining primary interviews, technical validation, and secondary evidence to ensure practical relevance and methodological rigor

The research approach combines a layered methodology that integrates primary interviews, rigorous secondary source triangulation, and technical validation exercises. Primary data was collected through structured interviews with laboratory directors, procurement leads, diagnostic developers, and service providers to capture operational priorities, procurement drivers, and innovation roadmaps. Secondary research synthesized peer-reviewed literature, regulatory guidance, and technical white papers to validate methodological distinctions across qualitative and quantitative testing approaches and to understand evolving performance standards for automated analyzers, automated plate readers, and molecular assays.

Technical validation involved cross-referencing method characteristics-such as throughput, time-to-result, and interpretive complexity-against documented laboratory workflows and published performance evaluations for genotypic and phenotypic methods. Supply chain and policy analyses incorporated trade data and public procurement patterns to assess vulnerability points and potential mitigation strategies. Throughout, findings were iteratively reviewed with subject matter experts to ensure accuracy and practical relevance. This mixed-methods design ensures that conclusions are grounded in real-world practice while reflecting the technical nuances of assay development, instrument integration, and service delivery.

Concluding perspective on aligning technological, operational, and commercial strategies to realize the clinical and public health benefits of advanced susceptibility testing

Antimicrobial susceptibility testing is at an inflection point where technological innovation, operational pressures, and policy dynamics converge to reshape diagnostic practice. The continued push toward automation, complementary genotypic methods, and data-enabled stewardship tools promises to improve diagnostic speed and clinical decision-making, while also introducing new requirements for validation, interoperability, and workforce competencies. Supply chain resilience and adaptable commercial models will influence how quickly laboratories and research organizations can adopt new platforms and assays.

Stakeholders that align investment with clear use-case prioritization-distinguishing the needs of clinical diagnostics, drug discovery and development, and epidemiology-will capture the greatest value. By integrating product-level strategies, regional tailoring, and partnerships that bridge technical and commercial gaps, organizations can both mitigate near-term risks and position themselves for sustained impact. The path forward favors pragmatic innovation that is interoperable, validated in real-world settings, and supported by service models that address the full lifecycle of instruments, reagents, and testing programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of rapid microfluidic AST systems enabling same shift antibiotic optimization
  • 5.2. Integration of AI-driven image analysis in AST platforms for enhanced result accuracy
  • 5.3. Expansion of next-generation sequencing-based AST assays for comprehensive resistance profiling
  • 5.4. Emergence of automated disc diffusion readers reducing manual interpretation variability
  • 5.5. Growing demand for multiplexed AST panels targeting multidrug-resistant pathogen detection
  • 5.6. Regulatory approval acceleration for microplate-based AST kits to meet urgent clinical needs
  • 5.7. Strategic partnerships between diagnostic firms and AI startups to co-develop AST analytics
  • 5.8. Implementation of cloud-based AST data management systems for real-time surveillance reporting

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Susceptibility Testing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Automated Systems
      • 8.1.1.1. Automated Analyzers
      • 8.1.1.2. Automated Plate Readers
    • 8.1.2. Manual Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Antibiotic Susceptibility Kits
    • 8.2.2. Microbial Identification Kits
  • 8.3. Services
    • 8.3.1. Analytical Testing Services
    • 8.3.2. Custom Testing Solutions

9. Antimicrobial Susceptibility Testing Market, by Test Type

  • 9.1. Antibacterial Susceptibility Testing
  • 9.2. Antifungal Susceptibility Testing
  • 9.3. Antiparasitic Susceptibility Testing
  • 9.4. Antiviral Susceptibility Testing

10. Antimicrobial Susceptibility Testing Market, by Method

  • 10.1. Qualitative Methods
    • 10.1.1. Agar Dilution
    • 10.1.2. Automated Ast
    • 10.1.3. Disk Diffusion
    • 10.1.4. Genotypic Method
  • 10.2. Quantitative Methods
    • 10.2.1. Broth Macrodilution
    • 10.2.2. Etest Method

11. Antimicrobial Susceptibility Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery & Development
  • 11.3. Epidemiology

12. Antimicrobial Susceptibility Testing Market, by End User

  • 12.1. Academic & Government Research Institutes
  • 12.2. Hospitals & Diagnostic Centers
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Antimicrobial Susceptibility Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimicrobial Susceptibility Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimicrobial Susceptibility Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Accelerate Diagnostics, Inc.
    • 16.3.2. Alifax S.r.l.
    • 16.3.3. Becton, Dickinson and Company
    • 16.3.4. Bio-Rad Laboratories, Inc.
    • 16.3.5. BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
    • 16.3.6. Biological Safety Solutions Ltd/Oy
    • 16.3.7. BioMerieux SA
    • 16.3.8. Bruker Corporation
    • 16.3.9. Creative Diagnostics
    • 16.3.10. Danaher Corporation
    • 16.3.11. Erba Lachema s.r.o.
    • 16.3.12. Eurofins Scientific SE
    • 16.3.13. F. Hoffmann-La Roche AG
    • 16.3.14. Himedia Laboratories Private Limited
    • 16.3.15. INTEGRA Biosciences AG
    • 16.3.16. Laboratorios Conda, S.A.
    • 16.3.17. Launch Diagnostics Limited
    • 16.3.18. Leading Biology, Inc.
    • 16.3.19. Liofilchem S.r.l.
    • 16.3.20. Mast Group Ltd.
    • 16.3.21. MP Biomedicals, LLC
    • 16.3.22. Pfizer Inc.
    • 16.3.23. Qiagen N.V.
    • 16.3.24. QuantaMatrix Inc.
    • 16.3.25. Resistell AG
    • 16.3.26. Synoptics Group
    • 16.3.27. Thermo Fisher Scientific Inc.
    • 16.3.28. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA ANTIMICROBIAL SUSCEPTI